


**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

|                                                                                                                                                                                                                                                                                                              |            |                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| <b>1. Your Name: Kenneth I. Moch</b>                                                                                                                                                                                                                                                                         |            |                 |
| <b>2. Your Title: President &amp; CEO, Cognition Therapeutics, Inc.</b>                                                                                                                                                                                                                                      |            |                 |
| <b>3. The Entity(ies) You are Representing: Cognition Therapeutics, Inc.</b>                                                                                                                                                                                                                                 |            |                 |
| <b>4. Are you testifying on behalf of the Federal, or a State or local government entity?</b>                                                                                                                                                                                                                | <b>Yes</b> | <b>No<br/>X</b> |
| <b>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b> |            |                 |
| None                                                                                                                                                                                                                                                                                                         |            |                 |
| <b>6. Please attach your curriculum vitae to your completed disclosure form.</b>                                                                                                                                                                                                                             |            |                 |

Signature:  \_\_\_\_\_

Date: October 2, 2017

Kenneth I. Moch joined Cognition as President & CEO in October 2016 to lead the company's efforts to develop new medicines to treat Alzheimer's disease and potentially other neurocognitive disorders. Cognition's lead compound, CT1812, is a proprietary first-in-class, orally available small molecule that displaces and clears bound beta amyloid oligomers and inhibits the binding of A $\beta$  oligomers to receptor complexes on synapses. CT1812 is currently in Phase 1/2 clinical testing in patients with Alzheimer's disease.

Ken is a proven leader who has demonstrated the ability to build and transform companies. His overarching skill is creating results-oriented environments and constructing strong, efficient teams which produce superior individual and team performance, thereby maximizing the opportunity for the technology and products to succeed. In an industry faced with constant challenges, he has also restructured and repositioned companies, doing so in ways that allowed the organizations to be successfully rebuilt when the hurdles were overcome.

Ken has played a key role in building five life science companies, resulting in multiple marketed products. He has been responsible for the successful completion of more than 30 public offerings and private placements, many under difficult market and/or product development conditions, and has negotiated corporate partnering deals with numerous large pharmaceutical companies. Ken is adept at translating cutting-edge science into understandable presentations that attract investor and corporate partner interest and support. In addition, Ken has a deep knowledge of the complexities of the regulatory process, and has been actively involved in assembling multidisciplinary teams and working with key opinion leaders to design and implement clinical trial strategies and deal with regulatory issues.

As a consultant, Ken has been a strategic and tactical advisor and mentor to CEOs, providing realistic, experience-based advice, and has served as a troubleshooter for companies which have encountered financial, partnering or regulatory issues. He has also been called upon by investors to help Boards solve difficult managerial and strategic situations, actively participating in fixing problems with the ability to step in as an interim executive if needed.

As a result of his experiences as an executive, consultant and industry advocate, Ken has strong, long-standing professional and personal relationships with hundreds of CEOs, CFOs and heads of business development of public and private biotechnology and large-cap pharmaceutical companies, as well as with venture capitalists and public equity investors.

Prior to Cognition, Ken was a managing director of The Salutrmed Group, LLC, a boutique consulting firm providing strategic and scientific advice to CEOs and Boards of public and private life science companies at all of stages of their evolution.

Ken served as President & CEO of Chimerix, Inc., from April 2010 to April 2014, having joined the company in June 2009 as Chief Operating Officer. Ken reorganized and rebuilt the company's infrastructure and management team, and focused the company on the commercial opportunities for brincidofovir/CMX001 as a broad-spectrum antiviral drug for the prevention and treatment of life-threatening dsDNA viral infections in immunocompromised patients. As part of these efforts, Ken raised over \$60 million from venture investors, negotiated a \$81 million BARDA contract for the continued development of brincidofovir as a biodefense agent for the treatment of smallpox, and led the market-opening \$118 million IPO that fully funded the Phase 3 SUPPRESS CMV trial of brincidofovir.

In December 2008, at the request of the venture investors, Ken stepped in as the President & CEO of BioMedical Enterprises, Inc., a San Antonio, Texas manufacturer and marketer of memory metal (nitinol) orthopedic implants. During his tenure with BME he completely reinvigorated the firm's product development efforts and reorganized the management structure, putting in place the management team which led the company through its acquisition by Johnson & Johnson.

From 2006 to 2008, Ken was Managing Director, Healthcare Investment Banking with ThinkEquity Partners in New York City, a 300-person boutique investment bank, where he provided financing and strategic advice to dozens of life science companies.

From 1995 to 2006, Ken was with Alteon Inc., a public biotechnology company developing small molecule therapeutics for cardiovascular aging and diabetic complications. Ken joined Alteon in February 1995 as Senior Vice President, Finance & Business Development and CFO. He was elected President & CEO of Alteon in 1998 and Chairman in 2001.

From 1990 to 1995, Ken served as President & CEO of Biocyte Corporation, the cellular therapy company that pioneered the collection and commercial application of cord blood stem cells in transplantation and cellular therapy. During his tenure, Ken launched the first cord blood storage bank, which serves as the model for all current such businesses. From the first cord blood stem cell transplant, which was directly supported by Biocyte, over 35,000 such transplants have now been performed. Prior to Biocyte, he was a founder and the Managing General Partner of Catalyst Ventures, a venture capital partnership focused on the creation of early stage biomedical and high-technology companies in the Baltimore-Washington region.

From 1982 to 1988, Ken served as Vice President of The Liposome Company, Inc., one of the first companies developing liposomal drug delivery products for oncology and infectious diseases. As a co-founder, Ken played a key role in all aspects of the company's growth from a private start-up research laboratory to a publicly held biopharmaceutical firm. From 1980 to 1982, Ken was a management consultant with McKinsey & Company, Inc. He previously was a medical device and biopharmaceutical consultant with Channing, Weinberg & Company, Inc. (The Wilkerson Group).

Building on his longstanding interest in health policy, Ken has served for over a decade on the Board of the Biotechnology Innovation Organization (BIO), where he is currently chairs BIO's Bioethics Committee and co-chairs the Emerging Company Section's Policy Subcommittee. He is a past Chairman of BioNJ and a past member of the Executive Committee of the New York Biotechnology Association. Ken is a founding member of the NYU Working Group on Compassionate Use and Pre-Approval Access. He has been a frequent speaker on patient advocacy and the ethical issues surrounding access to experimental medicines, and has authored or co-authored numerous articles including a Wall Street Journal Op-Ed entitled, "*Wanted: Guidelines for Access to Experimental Drugs.*"

Ken currently serves on the Board of Zynerba Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, and Gamida Cell, a cell and immune therapy company. He also served for over a decade as a member of the Board of M2Gen, the personalized medicine subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Ken received his A.B. in biochemistry with a minor in health policy from Princeton University, and an M.B.A. with emphasis in finance and marketing from the Stanford Graduate School of Business.